GDTC
CytoMed Therapeutics LtdPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 31 CytoMed Therapeutics reported full-year 2025 financial results with…
- B May 13 1 insider buy $128.8K at $1.15
- B Jul 14 to Jul 20 2 days of insider buys: $300.0K by 1 insider, avg $1.50
- X Jul 31 Short interest falls 81.2% to 5.7K
- X Aug 14 Short interest falls 25.6% to 4.2K
- X Aug 31 Short interest jumps 51.4% to 6.4K
- X Sep 15 Short interest falls 43.2% to 3.6K
- X Sep 30 Short interest jumps 372.4% to 17.1K
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $428.8K. No open-market sales.
- TrendRANGE
3% above its 50-day average.
Who's buying
13F| Top holder | Shares | Value |
|---|---|---|
| UBS Group AG | 4,831 | $5.0K |
| OSAIC HOLDINGS, INC. | 21 | $21.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Oct 2024Price is below the lowest target. Median implies +349%.Targets as of Oct 26, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 10, 2024 | Benchmark REITERATE | Speculative Buy |
| Jun 11, 2024 | Benchmark REITERATE | Speculative Buy |
| Dec 4, 2023 | Benchmark REITERATE | Speculative Buy |
| Jul 21, 2023 | Benchmark INITIATE | Speculative Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jul 20, 2026 | Choo Chee Kong Director | BUY | $150.0K |
| Jul 14, 2026 | Choo Chee Kong Director | BUY | $150.0K |
| May 13, 2026 | Choo Chee Kong Director | BUY | $128.8K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
9 filings · 1 bullish · 2 bearish · 1 mixed · 5 neutral- NEUTRAL SC 13G/AOct 23, 2026
mDR Ltd filed an amended Schedule 13G disclosing a 9.984% passive stake in CytoMed Therapeutics as…
Monitor for further share sales by mDR Ltd, as the reduction from prior holdings may signal gradual exit. Any conversion to a 13D filing would indicate activist intent.
- NEUTRAL SC 13D/AOct 16, 2026
Chairman Choo Chee Kong filed an amended Schedule 13D reporting open-market purchases of 29,250…
The chairman's small open-market purchases signal confidence at current levels but are not material relative to his existing 25%+ stake. Monitor for any future escalation in stake size or changes to…
- NEUTRAL SC 13D/AOct 13, 2026
Chairman Choo Chee Kong filed an amended Schedule 13D disclosing open-market purchases of 62,000…
The Chairman's small open-market buy signals continued alignment but is not a material catalyst. Monitor for any future escalation in stake or strategic demands, as the activist posture remains…
- BEARISH 6-KOct 9, 2026
CytoMed Therapeutics received a Nasdaq deficiency notice on October 6, 2026, for failing to…
Monitor the company's stock price for any sustained recovery above $1.00 over ten consecutive business days. The next key date is April 5, 2027, when the initial compliance period expires. A reverse…
All GDTC filing & press-release reports (9)
- SC 13G/A reportOct 23, 2026
- SC 13D/A reportOct 16, 2026
- SC 13D/A reportOct 13, 2026
- 6-K reportOct 9, 2026
- 6-K reportSep 30, 2026
- 6-K reportMay 15, 2026
- 6-K reportMay 11, 2026
- 6-K reportMar 31, 2026
- 20-F reportMar 31, 2026